Dr Dana Maria Carabulea, DDS | |
10721 Equestrian Dr, North Tustin, CA 92705-2427 | |
(714) 943-8357 | |
(714) 417-9821 |
Full Name | Dr Dana Maria Carabulea |
---|---|
Gender | Female |
Speciality | Dentist - General Practice |
Location | 10721 Equestrian Dr, North Tustin, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1568603223 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1223G0001X | Dentist - General Practice | 43585 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Dana Maria Carabulea, DDS 10721 Equestrian Dr, North Tustin, CA 92705-2427 Ph: (714) 943-8357 | Dr Dana Maria Carabulea, DDS 10721 Equestrian Dr, North Tustin, CA 92705-2427 Ph: (714) 943-8357 |
News Archive
Researchers in the Duke Institute for Genome Sciences & Policy have developed a model for predicting risk of recurrence in early stage colon cancer patients, and have used the model to also predict sensitivity to chemotherapy and targeted therapy regimens.
ImmunoCAP, the worldwide leader of in vitro allergy diagnostics, is pleased to present the results of the largest cross-sectional allergy study ever conducted. The landmark study, announced today by Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information, and services, includes test results from over 2 million patients.
Insulin resistance affects tens of millions of Americans and is a big risk factor for heart disease. Yet, some people with the condition never develop heart disease, while some experience moderate coronary blockages. Others, though, get severe atherosclerosis - multiple blockages and deterioration of coronary arteries characterized by thick, hard, plaque-ridden arterial walls.
In a research paper recently uploaded to the bioRxiv* preprint server by Poston et al. (August 8th, 2021), common host factors amongst several zoonotic pathogens are explored by CRISPR-Cas9 screening in human lung cells, focusing in particular on the betacoronavirus genus.
Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years is $1.99 million. Subject to satisfactory progress by Sanaria, continued funding for a third year will bring the total to nearly $3 million.
› Verified 9 days ago